Novartis drops up to $1.5B for ADC specialist Myricx, continuing cancer spending spree

Summary

Novartis is acquiring Myricx Bio for up to $1.5 billion to gain access to its N-myristoyltransferase inhibitor payload platform for developing next-generation antibody-drug conjugates in oncology.